Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jason Gotlib

Showing results (1-10 of 246) with videos related to

Pageof 25
Sort By:
Current Hematology Reports|December 22, 2004
Farnesyltransferase inhibitor therapy in acute myelogenous leukemiaJason Gotlib
Current Hematologic Malignancy Reports|September 26, 2015
Tyrosine Kinase Inhibitors and Therapeutic Antibodies in Advanced Eosinophilic Disorders and Systemic MastocytosisJason Gotlib
American Journal of Hematology|October 22, 2015
World Health Organization-defined eosinophilic disorders: 2015 update on diagnosis, risk stratification, and managementJason Gotlib
Blood|January 14, 2021
What your HαT says about youJason Gotlib
Blood|January 22, 2026
Introduction to a How I Treat series on chronic myeloid leukemiaJason Gotlib
Acta Haematologica|July 5, 2005
Molecular classification and pathogenesis of eosinophilic disorders: 2005 updateJason Gotlib
Hematology. American Society of Hematology. Education Program|December 9, 2022
Available and emerging therapies for bona fide advanced systemic mastocytosis and primary eosinophilic neoplasmsJason Gotlib
Hematology. American Society of Hematology. Education Program|December 10, 2013
JAK inhibition in the myeloproliferative neoplasms: lessons learned from the bench and bedsideJason Gotlib
Current Opinion in Hematology|January 15, 2010
Eosinophilic myeloid disorders: new classification and novel therapeutic strategiesJason Gotlib
Hematology/Oncology Clinics of North America|July 5, 2017
Tyrosine Kinase Inhibitors in the Treatment of Eosinophilic Neoplasms and Systemic MastocytosisJason Gotlib
Pageof 25

Showing results (1-10 of 246) with videos related to

Sort By:
Pageof 25
Current Hematology Reports|December 22, 2004
Farnesyltransferase inhibitor therapy in acute myelogenous leukemiaJason Gotlib
Current Hematologic Malignancy Reports|September 26, 2015
Tyrosine Kinase Inhibitors and Therapeutic Antibodies in Advanced Eosinophilic Disorders and Systemic MastocytosisJason Gotlib
American Journal of Hematology|October 22, 2015
World Health Organization-defined eosinophilic disorders: 2015 update on diagnosis, risk stratification, and managementJason Gotlib
Blood|January 14, 2021
What your HαT says about youJason Gotlib
Blood|January 22, 2026
Introduction to a How I Treat series on chronic myeloid leukemiaJason Gotlib
Acta Haematologica|July 5, 2005
Molecular classification and pathogenesis of eosinophilic disorders: 2005 updateJason Gotlib
Hematology. American Society of Hematology. Education Program|December 9, 2022
Available and emerging therapies for bona fide advanced systemic mastocytosis and primary eosinophilic neoplasmsJason Gotlib
Hematology. American Society of Hematology. Education Program|December 10, 2013
JAK inhibition in the myeloproliferative neoplasms: lessons learned from the bench and bedsideJason Gotlib
Current Opinion in Hematology|January 15, 2010
Eosinophilic myeloid disorders: new classification and novel therapeutic strategiesJason Gotlib
Hematology/Oncology Clinics of North America|July 5, 2017
Tyrosine Kinase Inhibitors in the Treatment of Eosinophilic Neoplasms and Systemic MastocytosisJason Gotlib
Pageof 25